US2009264367A1PendingUtilityA1

5-cnac as oral delivery agent for parathyroid hormone fragments

65
Assignee: AZRIA MOISEPriority: Aug 17, 2001Filed: Jul 1, 2009Published: Oct 22, 2009
Est. expiryAug 17, 2021(expired)· nominal 20-yr term from priority
Inventors:Moise AzriaSimon David Bateman
A61P 5/18A61K 38/29A61K 31/198A61K 47/183A61P 19/08A61P 19/00A61K 9/4858A61P 19/10A61K 47/18
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A pharmaceutical composition for oral delivery comprising recombinant PTH (1-34) and N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) disodium salt. 
     
     
         23 . A method for orally administering an effective dose of PTH comprising orally administering to a patient in need of PTH a pharmaceutical composition comprising recombinant PTH (1-34) and 5-CNAC disodium salt. 
     
     
         24 . A method of stimulating new bone formation comprising orally administering to a patient in need of new bone formation a pharmaceutical composition comprising a therapeutically effective amount of recombinant PTH (1-34) and 5-CNAC disodium salt. 
     
     
         25 . A method of treating osteoporosis comprising orally administering to a patient in need of said treatment a pharmaceutical composition comprising a therapeutically effective amount of recombinant PTH (1-34) and 5-CNAC disodium salt.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.